NDC Compounded Drug 71170-500-25 Norepinephrine; Sodium Chloride; Sodium Metabisulfite
Injection, Solution Intravenous
Compounded Drug Product Information
NDC Crossover Products Matching Norepinephrine; Sodium Chloride; Sodium Metabisulfite
NDC crossover of Norepinephrine Bitartrate 4mg Added To 250ml Of 5% Dextrose with NDC 71170-500 a human compounded drug with other similar products matching the same substance name (Norepinephrine; Sodium Chloride; Sodium Metabisulfite) and the same administration route (intravenous) or dosage form (injection, solution).
NDC | Proprietary Name | Non-Proprietary Name | Package Desc | Dosage Form | Route Name | Company Name |
---|---|---|---|---|---|---|
71170-510-25 | Norepinephrine Bitartrate 8mg Added To 250ml Of 5% Dextrose | Norepinephrine Bitartrate 8mg Added To 250ml Of 5% Dextrose | 250 mL in 1 BAG | Injection, Solution | Intravenous | Apollo Care, Llc |
Frequently Asked Questions
What is the NDC number assigned to Norepinephrine Bitartrate 8mg Added To 250ml Of 5% Dextrose?
Norepinephrine Bitartrate 8mg Added To 250ml Of 5% Dextrose was assigned by its manufacturer with NDC product code 71170-500. This product is a drug classified as a human compounded drug. Compounded drugs are medications created by combining or altering existing drugs to meet the specific needs of certain patients. The NDC directory only includes information about compounded drugs from facilities that choose to assign NDC numbers to their products.
Which are the NDC package codes for Norepinephrine Bitartrate 8mg Added To 250ml Of 5% Dextrose?
The NDC package code 71170-500-25 was assigned to a 250 mL in 1 BAG of norepinephrine; sodium chloride; sodium metabisulfite administered intravenous via injection, solution.
Who manufactures this product?
Norepinephrine Bitartrate 8mg Added To 250ml Of 5% Dextrose is manufactured by an outsourced facility and labeled by Apollo Care, Llc. All compounded drugs included in the NDC directory are classified as "Outsourcing Facility Compounded Human Drug Product (Exempt from Approval Requirements)". Outsourcing facilities are a type of drug compounding facility regulated under Section 503B of the FD&C Act could be eligible for exemptions from drug registration if they meet all the conditions specified under Section 503B.
Which are the NDC crossover matchings for this product?
We found 1 matching products that have the same substance, dosage form and administration route. The matching products are manufactured by Apollo Care, LLC with NDC product codes 71170-510-25.